Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 12,298 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Infusion Procedure Clear all

Conditions: Prostate Cancer
Interventions: Cabazitaxel (XRP6258), Prednisone (or Prednisolone); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 21
States / cities: Muscle Shoals, Alabama • Hot Springs, Arkansas • Anaheim, California + 18 more

Conditions: Advanced Renal Cell Carcinoma, Advanced Melanoma
Interventions: Sitagliptin, Pembrolizumab; Drug
Lead sponsor: Fernando Maciel Barbosa; Other
Eligibility: 18 Years to 99 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
Interventions: JCAR017, Lymphodepleting, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Celgene; Industry
Eligibility: Up to 25 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 9
States / cities: Duarte, California • Redwood City, California • St. Petersburg, Florida + 6 more

Conditions: Advanced Solid Tumor, Metastatic Breast Cancer
Interventions: Abraxane, ORIN1001; Drug
Lead sponsor: Orinove, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 20
States / cities: Gilbert, Arizona • Tucson, Arizona • Burbank, California + 16 more

Conditions: Dietary Modification
Interventions: Continuous Gastric Feeding, Bolus Gastric Feeding; Other
Lead sponsor: Akron Children's Hospital; Other
Eligibility: 1 Month to 12 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 6
States / cities: Gainesville, Florida • Lebanon, New Hampshire • Akron, Ohio + 3 more

Conditions: Alzheimer Disease
Interventions: sabirnetug, Placebo; Drug
Lead sponsor: Acumen Pharmaceuticals; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 44
States / cities: Carlsbad, California • Fullerton, California • Irvine, California + 40 more

Conditions: Primary Graft Failure, Secondary Graft Failure
Interventions: Fludarabine, Cyclophosphamide, Total Body Irradiation, Hematopoietic stem cell infusion; Drug · Radiation · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2032
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Fabry Disease
Interventions: Agalsidase beta; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Coral Springs, Florida • Decatur, Georgia • Baltimore, Maryland + 3 more

Conditions: Esophageal Cancer
Interventions: fluorouracil, oxaliplatin, conventional surgery, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 143
States / cities: Mobile, Alabama • Anchorage, Alaska • Bentonville, Arkansas + 92 more

Conditions: Persistent Pulmonary Hypertension, Respiratory Failure
Interventions: Intravenous Sildenafil, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: Up to 72 Hours
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 7
States / cities: Aurora, Colorado • Chicago, Illinois • Buffalo, New York + 2 more

Conditions: COVID-19
Interventions: Brilacidin, Placebo, Standard of Care (SoC); Drug
Lead sponsor: Innovation Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Winfield, Illinois • Toledo, Ohio

Conditions: Melanoma
Interventions: Nivolumab - Arm A, Nivolumab + Ipilimumab - Arm B; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, MDS, Refractory Anemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Non-Hodgkin's Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
Interventions: filgrastim, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, umbilical cord blood transplantation, total-body irradiation; Biological · Drug · Procedure + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 55 Years
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2019
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Seattle, Washington

Conditions: Acute HIV Infection
Interventions: VRC07-523LS, PGT121.414.LS, Placebo, ART; Biological · Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 9
States / cities: Birmingham, Alabama • Aurora, Colorado • Atlanta, Georgia + 6 more

Conditions: Cervical Cancer
Interventions: Zalifrelimab, Balstilimab; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 13
States / cities: Goodyear, Arizona • Duarte, California • Miami, Florida + 10 more

Conditions: Crohn's Disease
Interventions: CT-P13, Remicade; Biological
Lead sponsor: Celltrion; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Alcoholic Hepatitis, Sepsis
Interventions: Vitamin C, Dextrose 5% in water; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Primary Central Nervous System (CNS) Lymphoma, Secondary Central Nervous System Lymphoma
Interventions: MB-CART19.1 Cellular Therapy; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Metastatic Breast Cancer With Intracranial Metastases
Interventions: cabazitaxel, lapatinib; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 4
States / cities: Fort Myers, Florida • St. Petersburg, Florida • Cincinnati, Ohio + 1 more

Conditions: Leukemia
Interventions: rituximab, cyclophosphamide, pentostatin, Alemtuzumab; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2018
U.S. locations: 143
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 112 more

Conditions: Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma
Interventions: Aldesleukin, Autologous CD8+ SLC45A2-specific T Lymphocytes, Cyclophosphamide, Ipilimumab; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Covid19, Corona Virus Infection, SARS-CoV Infection, ARDS, Coronavirus
Interventions: Umbilical Cord Lining Stem Cells (ULSC), Placebo (carrier control); Biological · Other
Lead sponsor: Restem, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Miami, Florida • Sioux Falls, South Dakota

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Radium-223 dichloride (Xofigo, BAY 88-8223), Pembrolizumab; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: San Marcos, California

Conditions: B-cell Acute Lymphoblastic Leukemia (B-ALL)
Interventions: Surovatamig; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 12
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 9 more

Search by objective public record fields.

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Sitagliptin With Pembro in RCC and Melanoma

A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer

COntinuous vs BOlus Nasogastric Feeding in Mechanically Ventilated Pediatric Patients 2

A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation

A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta

S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction

Study of Sildenafil to Treat Newborns With Persistent Pulmonary Hypertension

A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19

Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission

A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)

Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease

Vitamin C Infusion for TReatment in Sepsis and Alcoholic Hepatitis

A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)

Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases

Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL

Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS

Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia